180 related articles for article (PubMed ID: 21682877)
1. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study.
Perroud MW; Honma HN; Barbeiro AS; Gilli SC; Almeida MT; Vassallo J; Saad ST; Zambon L
J Exp Clin Cancer Res; 2011 Jun; 30(1):65. PubMed ID: 21682877
[TBL] [Abstract][Full Text] [Related]
2. Autologous dendritic cell vaccines for non-small-cell lung cancer.
Hirschowitz EA; Foody T; Kryscio R; Dickson L; Sturgill J; Yannelli J
J Clin Oncol; 2004 Jul; 22(14):2808-15. PubMed ID: 15254048
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Sanborn RE; Ross HJ; Aung S; Acheson A; Moudgil T; Puri S; Hilton T; Fisher B; Coffey T; Paustian C; Neuberger M; Walker E; Hu HM; Urba WJ; Fox BA
J Immunother Cancer; 2017 Dec; 5(1):103. PubMed ID: 29258618
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
6. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.
Wang QT; Nie Y; Sun SN; Lin T; Han RJ; Jiang J; Li Z; Li JQ; Xiao YP; Fan YY; Yuan XH; Zhang H; Zhao BB; Zeng M; Li SY; Liao HX; Zhang J; He YW
Cancer Immunol Immunother; 2020 Jul; 69(7):1375-1387. PubMed ID: 32078016
[TBL] [Abstract][Full Text] [Related]
7. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells.
Hirschowitz EA; Foody T; Hidalgo GE; Yannelli JR
Lung Cancer; 2007 Sep; 57(3):365-72. PubMed ID: 17509725
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer.
Um SJ; Choi YJ; Shin HJ; Son CH; Park YS; Roh MS; Kim YS; Kim YD; Lee SK; Jung MH; Lee MK; Son C; Choi PJ; Chung J; Kang CD; Lee EY
Lung Cancer; 2010 Nov; 70(2):188-94. PubMed ID: 20223553
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
Li DP; Li W; Feng J; Chen K; Tao M
Oncol Res; 2015; 22(2):67-74. PubMed ID: 25706393
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.
Ge C; Li R; Song H; Geng T; Yang J; Tan Q; Song L; Wang Y; Xue Y; Li Z; Dong S; Zhang Z; Zhang N; Guo J; Hua L; Chen S; Song X
BMC Cancer; 2017 Dec; 17(1):884. PubMed ID: 29268708
[TBL] [Abstract][Full Text] [Related]
12. Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis.
Takahashi H; Shimodaira S; Ogasawara M; Ota S; Kobayashi M; Abe H; Morita Y; Nagai K; Tsujitani S; Okamoto M; Suzuki Y; Nakanishi Y; Yonemitsu Y;
Cancer Immunol Immunother; 2016 Sep; 65(9):1099-111. PubMed ID: 27448677
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer.
Hirschowitz EA; Mullins A; Prajapati D; Baeker T; Kloecker G; Foody T; Damron K; Love C; Yannelli JR
J Thorac Oncol; 2011 Jan; 6(1):169-73. PubMed ID: 21150468
[TBL] [Abstract][Full Text] [Related]
14. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
15. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
[TBL] [Abstract][Full Text] [Related]
16. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer.
Shi SB; Ma TH; Li CH; Tang XY
Tumori; 2012; 98(3):314-9. PubMed ID: 22825506
[TBL] [Abstract][Full Text] [Related]
17. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
Raez LE; Cassileth PA; Schlesselman JJ; Padmanabhan S; Fisher EZ; Baldie PA; Sridhar K; Podack ER
Cancer Gene Ther; 2003 Nov; 10(11):850-8. PubMed ID: 14605671
[TBL] [Abstract][Full Text] [Related]
18. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients.
Kimura H; Iizasa T; Ishikawa A; Shingyouji M; Yoshino M; Kimura M; Inada Y; Matsubayashi K
Anticancer Res; 2008; 28(2B):1229-38. PubMed ID: 18505060
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
Sebastian M; Papachristofilou A; Weiss C; Früh M; Cathomas R; Hilbe W; Wehler T; Rippin G; Koch SD; Scheel B; Fotin-Mleczek M; Heidenreich R; Kallen KJ; Gnad-Vogt U; Zippelius A
BMC Cancer; 2014 Oct; 14():748. PubMed ID: 25288198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
